Literature DB >> 9015110

Protective immunity against group A rotavirus infection and illness in infants.

D O Matson1.   

Abstract

Understanding of the protective effect provided by natural rotavirus infections against subsequent rotavirus infections is required for evaluating vaccine development programs. Prior studies of the protective efficacy of natural infections and correlates of natural protection are reviewed and results from several studies presented only in abstract form are summarized to provide a current assessment of knowledge in this area. Six cohort studies have reported rates for the protective efficacy of a natural rotavirus infection against subsequent infection, diarrhea, or severe diarrhea. These efficacy estimates ranged from 0 to 100% and are not directly comparable because of differences in methodology and population monitored. Results from other study designs also have been confusing, until recently. Recent studies have identified immunologic correlates of protection and studies from a cohort of intensely monitored Mexican children promise to provide a comprehensive assessment of the strength of the protective effect of natural rotavirus infection.

Entities:  

Mesh:

Year:  1996        PMID: 9015110     DOI: 10.1007/978-3-7091-6553-9_15

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  2 in total

1.  Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates.

Authors:  Xiaobo Wen; Dianjun Cao; Ronald W Jones; Jianping Li; Shousun Szu; Yasutaka Hoshino
Journal:  Vaccine       Date:  2012-08-09       Impact factor: 3.641

2.  Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine.

Authors:  Brigitte Cheuvart; Kathleen M Neuzil; A Duncan Steele; Nigel Cunliffe; Shabir A Madhi; Naveen Karkada; Htay Htay Han; Carla Vinals
Journal:  Hum Vaccin Immunother       Date:  2013-11-13       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.